These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35033866)

  • 21. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
    Krawczyk K; Śladowska K; Holko P; Kawalec P
    Front Pharmacol; 2023; 14():1223929. PubMed ID: 37745049
    [No Abstract]   [Full Text] [Related]  

  • 22. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
    Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
    Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review.
    Domański P; Piętak M; Staneta S; Fortuniak W; Kruczyk B; Kobiernik A; Bakuła P; Mydlak A; Demkow T; Sikora-Kupis B; Dumnicka P; Kucharz J
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541124
    [No Abstract]   [Full Text] [Related]  

  • 24. Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma.
    Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Hashimoto Y; Kondo T; Takagi T
    Jpn J Clin Oncol; 2023 Oct; 53(10):977-983. PubMed ID: 37519060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.
    Gerendash BS; Creel PA
    Onco Targets Ther; 2017; 10():5053-5064. PubMed ID: 29089775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
    George DJ; Hessel C; Halabi S; Michaelson MD; Hahn O; Walsh M; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; Morris MJ; Choueiri TK
    Oncologist; 2019 Nov; 24(11):1497-1501. PubMed ID: 31399500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma.
    Liu T; Jin Y; Dong M
    Clin Genitourin Cancer; 2023 Dec; 21(6):e449-e460. PubMed ID: 37271697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approaches to first-line treatment of advanced renal cell carcinoma.
    George DJ; Lee CH; Heng D
    Ther Adv Med Oncol; 2021; 13():17588359211034708. PubMed ID: 34527080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma.
    Takagi T
    Int J Urol; 2023 Sep; 30(9):705-713. PubMed ID: 36479730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma.
    Sato R; Matsushita Y; Takemura A; Sugiyama M; Watanabe K; Watanabe H; Tamura K; Motoyama D; Nagata M; Otsuka A; Furuse H; Miyake H
    Anticancer Res; 2024 Feb; 44(2):781-786. PubMed ID: 38307571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
    Meric-Bernstam F; Tannir NM; Iliopoulos O; Lee RJ; Telli ML; Fan AC; DeMichele A; Haas NB; Patel MR; Harding JJ; Voss MH; Owonikoko TK; Carthon B; Srinivasan R; Bendell JC; Jenkins Y; Whiting SH; Orford K; Bennett MK; Bauer TM
    Clin Cancer Res; 2022 Apr; 28(8):1540-1548. PubMed ID: 35140121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma.
    Anghelone A; Strusi A; Scala A; Panebianco M; Ciccarese C; Iacovelli R
    Expert Rev Anticancer Ther; 2023 Jul; 23(7):669-672. PubMed ID: 37246571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review.
    Brown J; Santini D; Charnley N; Ogareva A; Chisholm A; Jones R
    Cancer Treat Rev; 2024 Sep; 129():102792. PubMed ID: 38972135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma.
    Okumura H; Murase K; Oka S; Kizawa R; Yamaguchi T; Tanabe Y; Suyama K; Sakaguchi K; Urakami S; Miura Y
    Chemotherapy; 2024; 69(1):45-48. PubMed ID: 37820606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
    Aggen DH; Ager CR; Obradovic AZ; Chowdhury N; Ghasemzadeh A; Mao W; Chaimowitz MG; Lopez-Bujanda ZA; Spina CS; Hawley JE; Dallos MC; Zhang C; Wang V; Li H; Guo XV; Drake CG
    Clin Cancer Res; 2021 Jan; 27(2):608-621. PubMed ID: 33148676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023;6:339-348.
    Chadha J; Chahoud J
    Eur Urol Oncol; 2024 Feb; 7(1):172. PubMed ID: 37357090
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma.
    Parikh M; Bajwa P
    Semin Nephrol; 2020 Jan; 40(1):76-85. PubMed ID: 32130969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Powles T;
    Ann Oncol; 2021 Mar; 32(3):422-423. PubMed ID: 33271289
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
    Shiota M; Miyake H; Takahashi M; Oya M; Tsuchiya N; Masumori N; Matsuyama H; Obara W; Shinohara N; Fujimoto K; Nozawa M; Ohba K; Ohyama C; Hashine K; Akamatsu S; Kamba T; Mita K; Gotoh M; Tatarano S; Fujisawa M; Tomita Y; Mukai S; Ito K; Tanegashima T; Tokunaga S; Eto M;
    Cancer Immunol Immunother; 2023 Jun; 72(6):1903-1915. PubMed ID: 36729213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial.
    Rosellini M; Tassinari E; Marchetti A; Mollica V; Massari F
    Eur Urol; 2024 Jan; 85(1):97-98. PubMed ID: 37777426
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.